Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Serotonin Neuronal Function from the Bed to the Bench: Is This Really a Mirrored Way?

Etievant A, Lau T, Lucas G, Haddjeri N.

eNeuro. 2019 Jun 5;6(3). pii: ENEURO.0021-19.2019. doi: 10.1523/ENEURO.0021-19.2019. Print 2019 May/Jun. No abstract available.

2.

Rods contribute to the light-induced phase shift of the retinal clock in mammals.

Calligaro H, Coutanson C, Najjar RP, Mazzaro N, Cooper HM, Haddjeri N, Felder-Schmittbuhl MP, Dkhissi-Benyahya O.

PLoS Biol. 2019 Mar 1;17(3):e2006211. doi: 10.1371/journal.pbio.2006211. eCollection 2019 Mar.

3.

The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity.

Delcourte S, Ashby CR Jr, Rovera R, Kiss B, Adham N, Farkas B, Haddjeri N.

CNS Neurosci Ther. 2018 Dec;24(12):1129-1139. doi: 10.1111/cns.12867. Epub 2018 May 4.

4.

Inducing a long-term potentiation in the dentate gyrus is sufficient to produce rapid antidepressant-like effects.

Kanzari A, Bourcier-Lucas C, Freyssin A, Abrous DN, Haddjeri N, Lucas G.

Mol Psychiatry. 2018 Mar;23(3):587-596. doi: 10.1038/mp.2017.94. Epub 2017 May 9.

PMID:
28485406
5.

Stress Models of Depression: A Question of Bad Timing.

Delcourte S, Dkhissi-Benyahya O, Cooper H, Haddjeri N.

eNeuro. 2017 Apr 20;4(2). pii: ENEURO.0045-17.2017. doi: 10.1523/ENEURO.0045-17.2017. eCollection 2017 Mar-Apr. No abstract available.

6.

Asenapine modulates mood-related behaviors and 5-HT1A/7 receptors-mediated neurotransmission.

Delcourte S, Abrial E, Etiévant A, Rovera R, Arnt J, Didriksen M, Haddjeri N.

CNS Neurosci Ther. 2017 Jun;23(6):518-525. doi: 10.1111/cns.12698. Epub 2017 Apr 17.

PMID:
28417559
7.

Opposite control of mesocortical and mesoaccumbal dopamine pathways by serotonin2B receptor blockade: Involvement of medial prefrontal cortex serotonin1A receptors.

Devroye C, Haddjeri N, Cathala A, Rovera R, Drago F, Piazza PV, Artigas F, Spampinato U.

Neuropharmacology. 2017 Jun;119:91-99. doi: 10.1016/j.neuropharm.2017.04.001. Epub 2017 Apr 5.

PMID:
28390892
8.

The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons.

Matthäus F, Haddjeri N, Sánchez C, Martí Y, Bahri S, Rovera R, Schloss P, Lau T.

Eur Neuropsychopharmacol. 2016 Nov;26(11):1806-1817. doi: 10.1016/j.euroneuro.2016.09.001. Epub 2016 Sep 21.

PMID:
27665061
9.

[Astroglial modulation of deep brain stimulation in depression].

Etiévant A, Lucas G, Haddjeri N.

Med Sci (Paris). 2016 8-9;32(8-9):687-9. doi: 10.1051/medsci/20163208009. Epub 2016 Sep 12. French. No abstract available.

10.

Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats.

Pehrson AL, Hillhouse TM, Haddjeri N, Rovera R, Porter JH, Mørk A, Smagin G, Song D, Budac D, Cajina M, Sanchez C.

J Pharmacol Exp Ther. 2016 Sep;358(3):472-82. doi: 10.1124/jpet.116.233924. Epub 2016 Jul 11.

11.

Differential control of dopamine ascending pathways by serotonin2B receptor antagonists: New opportunities for the treatment of schizophrenia.

Devroye C, Cathala A, Haddjeri N, Rovera R, Vallée M, Drago F, Piazza PV, Spampinato U.

Neuropharmacology. 2016 Oct;109:59-68. doi: 10.1016/j.neuropharm.2016.05.024. Epub 2016 May 31.

PMID:
27260325
12.

Protein Kinases Alter the Allosteric Modulation of the Serotonin Transporter In Vivo and In Vitro.

Mnie-Filali O, Lau T, Matthaeus F, Abrial E, Delcourte S, El Mansari M, Pershon A, Schloss P, Sánchez C, Haddjeri N.

CNS Neurosci Ther. 2016 Aug;22(8):691-9. doi: 10.1111/cns.12562. Epub 2016 May 12.

PMID:
27171685
13.

Deep Brain Stimulation for Depression: Is It a Gray or White "Matter"?

Etiévant A, Lucas G, Haddjeri N.

Biol Psychiatry. 2016 Sep 15;80(6):e43-e44. doi: 10.1016/j.biopsych.2015.11.029. Epub 2016 Jan 26. No abstract available.

PMID:
26987628
14.

The Role of Astroglia in the Antidepressant Action of Deep Brain Stimulation.

Etiévant A, Lucas G, Dkhissi-Benyahya O, Haddjeri N.

Front Cell Neurosci. 2016 Jan 12;9:509. doi: 10.3389/fncel.2015.00509. eCollection 2015. No abstract available.

15.

Astroglial Control of the Antidepressant-Like Effects of Prefrontal Cortex Deep Brain Stimulation.

Etiévant A, Oosterhof C, Bétry C, Abrial E, Novo-Perez M, Rovera R, Scarna H, Devader C, Mazella J, Wegener G, Sánchez C, Dkhissi-Benyahya O, Gronfier C, Coizet V, Beaulieu JM, Blier P, Lucas G, Haddjeri N.

EBioMedicine. 2015 Jul 7;2(8):898-908. doi: 10.1016/j.ebiom.2015.06.023. eCollection 2015 Aug.

16.

A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant.

Bétry C, Overstreet D, Haddjeri N, Pehrson AL, Bundgaard C, Sanchez C, Mørk A.

Pharmacol Biochem Behav. 2015 Apr;131:136-42. doi: 10.1016/j.pbb.2015.02.011. Epub 2015 Feb 16.

PMID:
25697477
17.

Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania.

Abrial E, Bétourné A, Etiévant A, Lucas G, Scarna H, Lambás-Señas L, Haddjeri N.

Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu031. doi: 10.1093/ijnp/pyu031.

18.

Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory.

Bétry C, Etiévant A, Pehrson A, Sánchez C, Haddjeri N.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:38-46. doi: 10.1016/j.pnpbp.2014.12.002. Epub 2014 Dec 16.

PMID:
25524057
19.

Involvement of 5-HT₇ receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents.

Westrich L, Haddjeri N, Dkhissi-Benyahya O, Sánchez C.

Neuropharmacology. 2015 Feb;89:382-90.

20.

The peptidic antidepressant spadin interacts with prefrontal 5-HT(4) and mGluR(2) receptors in the control of serotonergic function.

Moha ou Maati H, Bourcier-Lucas C, Veyssiere J, Kanzari A, Heurteaux C, Borsotto M, Haddjeri N, Lucas G.

Brain Struct Funct. 2016 Jan;221(1):21-37. doi: 10.1007/s00429-014-0890-x. Epub 2014 Sep 19.

PMID:
25233810
21.

Astrocytes and gliotransmitters: new players in the treatment of major depression?

Etiévant A, Lambás-Señas L, Scarna H, Lucas G, Haddjeri N.

Curr Drug Targets. 2013 Oct;14(11):1295-307. Review.

PMID:
24010966
22.

Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats.

Abrial E, Etievant A, Bétry C, Scarna H, Lucas G, Haddjeri N, Lambás-Señas L.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:40-8. doi: 10.1016/j.pnpbp.2012.11.015. Epub 2012 Dec 8.

PMID:
23228462
23.

The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.

Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol. 2013 Jun;16(5):1115-27. doi: 10.1017/S1461145712001058. Epub 2012 Oct 22.

PMID:
23089374
24.

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.

Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C.

Eur Neuropsychopharmacol. 2013 Feb;23(2):133-45. doi: 10.1016/j.euroneuro.2012.04.006. Epub 2012 May 20.

PMID:
22612991
25.

Synergistic antidepressant-like action of gaboxadol and escitalopram.

Christensen T, Bétry C, Mnie-Filali O, Etievant A, Ebert B, Haddjeri N, Wiborg O.

Eur Neuropsychopharmacol. 2012 Oct;22(10):751-60. doi: 10.1016/j.euroneuro.2012.02.001. Epub 2012 Mar 9.

PMID:
22406239
26.

A role for the PKC signaling system in the pathophysiology and treatment of mood disorders: involvement of a functional imbalance?

Abrial E, Lucas G, Scarna H, Haddjeri N, Lambás-Señas L.

Mol Neurobiol. 2011 Dec;44(3):407-19. doi: 10.1007/s12035-011-8210-4. Epub 2011 Oct 5. Review.

PMID:
21983961
27.

Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action.

Zhong H, Haddjeri N, Sánchez C.

Psychopharmacology (Berl). 2012 Jan;219(1):1-13. doi: 10.1007/s00213-011-2463-5. Epub 2011 Sep 8. Review.

PMID:
21901317
28.

In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.

Bétry C, Etiévant A, Lambás-Señas L, McCreary AC, Haddjeri N.

Synapse. 2011 Oct;65(10):1042-51. doi: 10.1002/syn.20936. Epub 2011 May 3.

PMID:
21446003
29.

Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy.

Mnie-Filali O, Faure C, Lambás-Señas L, El Mansari M, Belblidia H, Gondard E, Etiévant A, Scarna H, Didier A, Berod A, Blier P, Haddjeri N.

Neuropsychopharmacology. 2011 May;36(6):1275-88. doi: 10.1038/npp.2011.13. Epub 2011 Feb 16.

30.

Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat.

Lucas G, Du J, Romeas T, Mnie-Filali O, Haddjeri N, Piñeyro G, Debonnel G.

PLoS One. 2010 Feb 16;5(2):e9253. doi: 10.1371/journal.pone.0009253.

31.

Therapeutic potential of 5-HT7 receptors in mood disorders.

Mnie-Filali O, Lambas-Señas L, Scarna H, Haddjeri N.

Curr Drug Targets. 2009 Nov;10(11):1109-17.

PMID:
19702552
32.

Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.

Etievant A, Bétry C, Arnt J, Haddjeri N.

Neurosci Lett. 2009 Aug 21;460(1):82-6. doi: 10.1016/j.neulet.2009.05.035. Epub 2009 May 18.

PMID:
19450663
33.

F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.

Assié MB, Mnie-Filali O, Ravailhe V, Benas C, Marien M, Bétry C, Zimmer L, Haddjeri N, Newman-Tancredi A.

Eur J Pharmacol. 2009 Apr 1;607(1-3):74-83.

PMID:
19326477
34.

Functional correlates for 5-HT(1A) receptors in maternally deprived rats displaying anxiety and depression-like behaviors.

Lambás-Señas L, Mnie-Filali O, Certin V, Faure C, Lemoine L, Zimmer L, Haddjeri N.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):262-8. doi: 10.1016/j.pnpbp.2008.11.017. Epub 2008 Dec 7.

PMID:
19111592
35.

Neurokinin-1 receptor antagonists modulate brain noradrenaline and serotonin interactions.

Haddjeri N, Blier P.

Eur J Pharmacol. 2008 Dec 14;600(1-3):64-70. doi: 10.1016/j.ejphar.2008.10.001. Epub 2008 Oct 9.

PMID:
18930727
36.

[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].

Mnie-Filali O, El Mansari M, Scarna H, Zimmer L, Sánchez C, Haddjeri N.

Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Review. French.

PMID:
18789789
37.

Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.

Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N.

J Psychopharmacol. 2009 Mar;23(2):177-89. doi: 10.1177/0269881108089586. Epub 2008 May 30.

PMID:
18515444
38.

5-HT7 receptor antagonists as a new class of antidepressants.

Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N.

Drug News Perspect. 2007 Dec;20(10):613-8. doi: 10.1358/dnp.2007.20.10.1181354. Review.

PMID:
18301795
39.

R-citalopram prevents the neuronal adaptive changes induced by escitalopram.

Mnie-Filali O, Faure C, Mansari ME, Lambás-Señas L, Bérod A, Zimmer L, Sánchez C, Haddjeri N.

Neuroreport. 2007 Oct 8;18(15):1553-6.

PMID:
17885600
40.

Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action.

Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, Lambas-Senas L, Wiborg O, Haddjeri N, Piñeyro G, Sadikot AF, Debonnel G.

Neuron. 2007 Sep 6;55(5):712-25.

41.

Effects of the serotonin 5-HT(7) receptor antagonist SB-269970 on the inhibition of dopamine neuronal firing induced by amphetamine.

Mnie-Filali O, Dahan L, Zimmer L, Haddjeri N.

Eur J Pharmacol. 2007 Sep 10;570(1-3):72-6. Epub 2007 Jun 5.

PMID:
17586491
42.

Effects of the 5-HT7 receptor antagonist SB-269970 on rat hormonal and temperature responses to the 5-HT1A/7 receptor agonist 8-OH-DPAT.

Faure C, Mnie-Filali O, Scarna H, Debonnel G, Haddjeri N.

Neurosci Lett. 2006 Aug 14;404(1-2):122-6. Epub 2006 Jun 8.

PMID:
16759802
43.

GABAergic network activation of glial cells underlies hippocampal heterosynaptic depression.

Serrano A, Haddjeri N, Lacaille JC, Robitaille R.

J Neurosci. 2006 May 17;26(20):5370-82.

44.

Long-term adaptive changes induced by serotonergic antidepressant drugs.

Faure C, Mnie-Filali O, Haddjeri N.

Expert Rev Neurother. 2006 Feb;6(2):235-45. Review.

PMID:
16466303
45.

Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.

Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol. 2007 Feb;10(1):31-40. Epub 2006 Feb 1.

PMID:
16448580
46.

Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity.

Mnie-Filali O, El Mansari M, Espana A, Sànchez C, Haddjeri N.

Neurosci Lett. 2006 Feb 27;395(1):23-7. Epub 2005 Dec 5.

PMID:
16330146
47.
48.

Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.

Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R.

J Psychiatry Neurosci. 2004 May;29(3):208-18.

49.

In-vivo modulation of central 5-hydroxytryptamine (5-HT1A) receptor-mediated responses by the cholinergic system.

Haddjeri N, Faure C, Lucas G, Mnie-Filali O, Chouvet G, Astier B, Renaud B, Blier P, Debonnel G.

Int J Neuropsychopharmacol. 2004 Dec;7(4):391-9. Epub 2004 May 12.

PMID:
15140278
50.

Electrophysiological evidence for the tonic activation of 5-HT(1A) autoreceptors in the rat dorsal raphe nucleus.

Haddjeri N, Lavoie N, Blier P.

Neuropsychopharmacology. 2004 Oct;29(10):1800-6.

Supplemental Content

Loading ...
Support Center